









Markets
/
Stocks
/
nasdaq-cers
/

Cerus Corp

CERS

1.300USD

+0.070+5.69%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

249.06MMarket Cap

LossP/E TTM



Cerus Corp

1.300

+0.070+5.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

88 / 207

Overall Ranking

236 / 4723

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.667

Target Price

+270.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Overvalued

The company’s latest PE is -12.30, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 150.59M shares, decreasing 7.25% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 19.21M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.28, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 60.13M, representing a year-over-year increase of 19.02%, while its net profit experienced a year-over-year increase of 1.18%.

Score

Industry at a Glance

Previous score

7.15

Change

0.13



Financials

5.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.27

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.99

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.29

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -12.30, which is 3.89% below the recent high of -12.77 and -9.90% above the recent low of -13.51.

Score

Industry at a Glance

Previous score

2.00

Change

-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 88/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 7.50, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Cerus Corp is 5.00, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.667

Target Price

+279.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Cerus Corp

CERS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.20, which is lower than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 1.40 and the support level at 1.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.41

Change

-0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.008

Sell

RSI(14)

45.535

Neutral

STOCH(KDJ)(9,3,3)

35.311

Neutral

ATR(14)

0.063

High Vlolatility

CCI(14)

-51.391

Neutral

Williams %R

66.667

Sell

TRIX(12,20)

-0.132

Sell

StochRSI(14)

58.015

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.234

Buy

MA10

1.260

Buy

MA20

1.267

Buy

MA50

1.309

Sell

MA100

1.332

Sell

MA200

1.477

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 78.56%, representing a quarter-over-quarter decrease of 2.95%. The largest institutional shareholder is Catherine Wood, holding a total of 19.21M shares, representing 10.02% of shares outstanding, with 10.60% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

20.66M

-0.77%

BlackRock Institutional Trust Company, N.A.

12.94M

+0.22%

Baker Bros. Advisors LP

19.35M

-0.65%

The Vanguard Group, Inc.

Star Investors

10.55M

+1.32%

Wasatch Global Investors Inc

Star Investors

8.32M

Amova Asset Management Co., Ltd.

6.19M

-4.19%

Geode Capital Management, L.L.C.

4.54M

+1.97%

Senvest Management, LLC

4.41M

-31.10%

State Street Global Advisors (US)

3.80M

-0.21%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.61, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.66. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.